CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend

WADA Notice: All three components are prohibited under WADA S2.2.4 (Growth Hormone-Releasing Peptides and their mimetics), both in- and out-of-competition on the 2026 WADA Prohibited List.

What is CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend?

CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend (6mg) co-formulates 2mg each of three mechanistically distinct GH secretagogue peptides: CJC-1295 with Drug Affinity Complex (DAC), a long-acting GHRH receptor agonist; ipamorelin, the first selective GHS-R1a agonist (GH without ACTH/cortisol); and GHRP-2, a potent non-selective GHS-R1a agonist (GH + ACTH/cortisol co-stimulation). CJC-1295 DAC activates a different receptor from ipamorelin and GHRP-2 - GHRHR vs GHS-R1a - via different intracellular cascades (Gs/cAMP vs Gq/Ca²⁺). This triple-mechanism formulation enables research into convergent GH axis stimulation from multiple upstream receptor inputs simultaneously. All three are WADA S2.2.4 prohibited. None is FDA-approved. Supplied for laboratory research only.

Chemical Properties

How Does the Triple Blend Work?

CJC-1295 DAC → GHRHR/Gs/cAMP (Extended Half-Life GHRH Agonist): CJC-1295 DAC incorporates a DAC lysine modification (maleimidopropionamide derivative), enabling covalent albumin binding post-reconstitution, extending plasma half-life to ~6–8 days in pharmacokinetic models (Jetté et al. 2005, PMID 15817669). At the pituitary GHRHR, CJC-1295 DAC activates Gs → adenylyl cyclase → cAMP → PKA → GH gene transcription and pulsatile exocytosis. Extended GHRHR occupancy produces sustained basal GH elevation while preserving pulsatility - a mechanistic contrast to receptor desensitisation from continuous GHRH infusion.

Ipamorelin → GHS-R1a/Gq/Ca²⁺ (Selective - No ACTH/Cortisol): Ipamorelin activates GHS-R1a via Gq/11 → PLCβ → IP3 → Ca²⁺ release in somatotrophs, producing pulsatile GH without ACTH, cortisol, prolactin, FSH, LH, or TSH co-elevation even at 200-fold GH-releasing ED50 (Raun et al. 1998, PMID 9849822). In this triple blend, ipamorelin provides GHS-R1a input without adrenal confound.

GHRP-2 → GHS-R1a/Gq/Ca²⁺ (Non-Selective - ACTH/Cortisol Co-Stimulation): GHRP-2 activates GHS-R1a via an identical Gq/Ca²⁺ mechanism as ipamorelin but with documented ACTH and cortisol co-stimulation (Muccioli et al. 2007, PMID 17622734). In this triple blend, GHRP-2 provides the mechanistic contrast to ipamorelin, enabling comparison of selective vs non-selective GHS-R1a agonism within the same experimental GH axis context.

What are the Potential Research Applications of the Triple Blend?

• Triple-pathway GH axis pharmacology: GHRHR + GHS-R1a dual input in primary pituitary somatotroph models and GHS-R1a/GHRHR co-transfected cell systems
• Ipamorelin vs GHRP-2 selectivity comparison within a fixed-ratio experimental system: quantifying ACTH/cortisol attributable to GHRP-2 vs ipamorelin GHS-R1a agonism
• CJC-1295 DAC albumin-binding pharmacokinetics: GHRHR occupancy modelling and sustained vs pulsatile GH secretory profile characterisation
• Synergistic Gs/cAMP + Gq/Ca²⁺ pathway convergence research: characterisation of non-overlapping signal cascade co-activation and GH pulse amplitude modulation

What are the Potential Side Effects of the Triple Blend?

• GHRP-2 component produces ACTH and cortisol co-stimulation in preclinical models; adrenal pathway activation must be controlled in hormonal endpoint studies
• Ipamorelin component: appetite stimulation via GHS-R1a in animal models
• CJC-1295 DAC: extended half-life (~6–8 days) produces prolonged GHRHR occupancy; receptor desensitisation kinetics differ from short-acting GHRH analogues
• No controlled toxicity data for this specific triple-peptide blend. No human safety data established. Data remains limited.

Risk & Handling

Handling Precautions

• Trained personnel only. All three are CNS-active GH secretagogues. Institutional biosafety review is strongly recommended. Reconstitute under aseptic conditions. PPE: gloves, lab coat, eye protection.

Exposure Risks

• Risk Tier: CRITICAL/HIGHEST - Three concurrent WADA-prohibited GH secretagogues. CJC-1295 DAC's extended half-life (~6–8 days) and GHRP-2's ACTH/cortisol co-stimulation create a compound adverse signal profile. No human safety data for triple-peptide blend. Long-term toxicity data absent for all three components. GH axis abuse potential is plausible but uncharacterised.

Storage

• Store at −20°C, sealed, light-protected, and dry. Reconstitute with bacteriostatic water aseptically. Do not re-freeze. Stable ≥24 months lyophilized.

FAQs

Why include both ipamorelin and GHRP-2 in the same blend?

Ipamorelin and GHRP-2 both activate GHS-R1a but with different selectivity profiles. Including both in a 1:1 ratio allows direct comparative research into selective vs non-selective GHS-R1a agonism within the same experimental GH axis system, with GHRP-2 providing the adrenal co-stimulation reference and ipamorelin providing the isolated GH signal.

How does CJC-1295 DAC's extended half-life affect study design?

CJC-1295 DAC's ~6–8 day half-life produces sustained GHRHR occupancy unlike the minutes-scale native GHRH. In cell models, this extended exposure changes receptor desensitisation and GH pulse pattern kinetics relative to short-acting GHRH. Washout periods of at least 5 half-lives (~30–40 days) should be considered in study designs where GHRHR baseline function is a required endpoint.

WADA classification for all three?

All three are classified under WADA S2.2.4 - Growth Hormone-Releasing Peptides and their mimetics. All are prohibited both in- and out-of-competition on the 2026 WADA Prohibited List.

References

• Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1−29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/

Disclaimer: CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Contact support@rcdbio.co for queries.